Keeping Up With Cornell
100% of donations to ClancysCure fund research conducted at Cornell. Summarized below are some of the key studies completed or underway:
Drug Repurposing To Aid Treatment of Canine Lymphoma
Traditional chemotherapeutic drugs have been used to extend quality of life, achieve clinical remissions, and slow cancer progression, but can be expensive. Additional safe, low cost therapies are needed for canine patients. This study will determine if a repurposed antibiotic drug can improve the outcome for dogs with large cell lymphoma.
2 the Outdoors: Canine Cancer Research at Cornell - April 7, 2019
Exciting progress on the identification of hemangiosarcoma and we are beyond thrilled to be mentioned via link in this article!
How dogs are teaching researchers new tricks for treating cancer
Studying lymphoma in canines yields insights into therapies for humans, while helping animals too. Read the full article here
The Danko Lab at the Baker Institute for Animal Health develops new Tool to study the genetic "switches" of tumor growth allowing for a deeper understanding of glioblastoma. Read the full article here
Oncologists at Cornell Eagerly Await Release of eBAT
Test results for the recently developed drug, eBAT, increased survival rates for dogs diagnosed with hemangiosarcoma, and has potential for use in humans.
eBAT, created at the University of Minnesota College of Veterinary Medicine, "specifically targets tumors while causing minimal damage to the immune system. Hemangiosarcoma is a vascular cancer, meaning it forms from blood vessels. eBAT was selected for this trial because it can simultaneously target the tumor and its vascular system,” said Daniel Vallera, Ph.D.,eBAT inventor and senior study author. Read the full article
Cornell's Lindsay Thalheim, VMD, DACVIM, is looks forward to the release of eBAT and hopes "this drug will soon become available to our patients who continue to succumb to this horrible disease on a daily basis."
Dogs Offer New Hope For Lymphoma Research
Cornell Chronicle Published October 26 2017
Cornell and Tufts University scientists have received a five-year, $2.5 million grant from the National Institutes of Health to use dogs as a model for studying cancer immunotherapies. Read the full article.
Radical Collaboration Sets Its Sights on Cancer Research
Two doctors – Lewis C. Cantley, M.S. ’73, Ph.D. ’75, and Kristy Richards ’90, Ph.D., M.D. – are growing radically collaborative research connections between Weill Cornell Medicine and the College of Veterinary Medicine, adding new discoveries to the university’s long history of research that benefits animals and people. They also are revamping the ways new generations of cancer drugs can be researched, tested and approved, which could dramatically shorten the timeline for new drug treatments and possibly save millions of lives. Read the full article.
Immunotherapy, Improving the Odds
Kristy Richards works with immunotherapies—especially monoclonal antibody therapies—aiming to make them effective for cancer patients—dogs and people.
One research challenge Richards and other immuno-oncologists face is that the human immune system is impossible to replicate in a dish. Richards’ answer has been to develop clinical trials in dogs—pet dogs already diagnosed with lymphoma. Not only do the dogs stand to benefit but also the pace and efficacy of drug development. Read the full article.
LindsayThalheim, VMD, DACVIM
Richard Cerione, Ph.D.
Scott Coonrod, Ph.D.